Poseida Therapeutics Future Growth
Future criteria checks 2/6
Poseida Therapeutics's earnings are forecast to decline at 4% per annum while its annual revenue is expected to grow at 23.1% per year. EPS is expected to grow by 9.3% per annum.
Key information
-4.0%
Earnings growth rate
9.3%
EPS growth rate
| Biotechs earnings growth | 30.0% |
| Revenue growth rate | 23.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 06 Aug 2024 |
Recent future growth updates
Recent updates
Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?
Jan 25Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow
Dec 09FDA lifts clinical hold on Poseida's prostate cancer cell therapy study
Nov 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 22 | -289 | -181 | -176 | 2 |
| 12/31/2025 | 43 | -235 | -137 | -133 | 3 |
| 12/31/2024 | 87 | -146 | 91 | 93 | 3 |
| 6/30/2024 | 88 | -113 | 0 | 2 | N/A |
| 3/31/2024 | 83 | -109 | -72 | -69 | N/A |
| 12/31/2023 | 65 | -123 | -95 | -92 | N/A |
| 9/30/2023 | 50 | -131 | -64 | -61 | N/A |
| 6/30/2023 | 157 | -29 | -11 | -7 | N/A |
| 3/31/2023 | 139 | -45 | -17 | -13 | N/A |
| 12/31/2022 | 130 | -64 | -31 | -27 | N/A |
| 9/30/2022 | 152 | -29 | -25 | -21 | N/A |
| 6/30/2022 | 35 | -142 | -126 | -123 | N/A |
| 3/31/2022 | 33 | -145 | -118 | -115 | N/A |
| 12/31/2021 | 31 | -125 | -105 | -103 | N/A |
| 9/30/2021 | N/A | -163 | -146 | -141 | N/A |
| 6/30/2021 | N/A | -155 | -137 | -130 | N/A |
| 3/31/2021 | N/A | -139 | -143 | -129 | N/A |
| 12/31/2020 | N/A | -130 | -130 | -113 | N/A |
| 9/30/2020 | N/A | -117 | -116 | -100 | N/A |
| 6/30/2020 | N/A | -104 | -105 | -89 | N/A |
| 3/31/2020 | N/A | -102 | -81 | -73 | N/A |
| 12/31/2019 | N/A | -87 | -70 | -65 | N/A |
| 9/30/2019 | N/A | -76 | -65 | -60 | N/A |
| 12/31/2018 | N/A | -44 | -39 | -38 | N/A |
| 9/30/2018 | N/A | -36 | -31 | -31 | N/A |
| 12/31/2017 | 3 | -20 | N/A | -23 | N/A |
| 12/31/2016 | 10 | -5 | N/A | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PSTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PSTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PSTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PSTX's revenue (23.1% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: PSTX's revenue (23.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PSTX's Return on Equity is forecast to be high in 3 years time